Elinogrel - CAS 936500-94-6
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
P2Y Receptor
Elinogrel is a P2Y12 antagonist displaying antiplatelet activity.
Brife Description:
P2Y12 antagonist
≥98% by HPLC
Canonical SMILES:
1.Plant extracts inhibit ADP-induced platelet activation in humans: their potential therapeutic role as ADP antagonists.
Jagroop IA Purinergic Signal. 2014;10(2):233-9. doi: 10.1007/s11302-013-9393-0. Epub 2013 Nov 5.
Adenosine diphosphate (ADP) plays a pivotal role in platelet activation. Platelet hyperactivity is associated with vascular disease and also has a key role in haemostasis and thrombosis. ADP activates platelets through three purinoceptor subtypes, the G(q)-coupled P2Y(1) receptor, G(i)-coupled P2Y(12) receptor and P2X(1) ligand-gated cation channel. Platelet ADP purinergic receptors are therefore suitable targets for antiplatelet drugs. Thienopyridines such as clopidogrel and ticlopidine, as well as other ADP receptor antagonists like prasugrel, ticagrelor, cangrelor and elinogrel have demonstrated clinical benefits via the inhibition of the selective purinergic ADP receptor, P2Y(12). However, they still have limitations in their mode of action and efficacy, like increased risk of bleeding. Thus, the ongoing pursuit to develop newer and more effective antiplatelet agents continues. There is a growing interest in the purinergic antiplatelet properties exhibited by plant extracts. This article considers the following: pomolic acid isolated from Licania pittieri, brazilin isolated from the heartwood of Caesalpinia sappan L, phylligenin isolated from the twigs of Muraltia vulpina, bark oil of Gonystylus velutinus, seed and bark extracts from Aesculus hippocastanum L.
2.A Comparative Study of Molecular Structure, pKa, Lipophilicity, Solubility, Absorption and Polar Surface Area of Some Antiplatelet Drugs.
Remko M;Remková A;Broer R Int J Mol Sci. 2016 Mar 19;17(3):388. doi: 10.3390/ijms17030388.
Theoretical chemistry methods have been used to study the molecular properties of antiplatelet agents (ticlopidine, clopidogrel, prasugrel, elinogrel, ticagrelor and cangrelor) and several thiol-containing active metabolites. The geometries and energies of most stable conformers of these drugs have been computed at the Becke3LYP/6-311++G(d,p) level of density functional theory. Computed dissociation constants show that the active metabolites of prodrugs (ticlopidine, clopidogrel and prasugrel) and drugs elinogrel and cangrelor are completely ionized at pH 7.4. Both ticagrelor and its active metabolite are present at pH = 7.4 in neutral undissociated form. The thienopyridine prodrugs ticlopidine, clopidogrel and prasugrel are lipophilic and insoluble in water. Their lipophilicity is very high (about 2.5-3.5 logP values). The polar surface area, with regard to the structurally-heterogeneous character of these antiplatelet drugs, is from very large interval of values of 3-255 Ų. Thienopyridine prodrugs, like ticlopidine, clopidogrel and prasugrel, with the lowest polar surface area (PSA) values, exhibit the largest absorption. A high value of polar surface area (PSA) of cangrelor (255 Ų) results in substantial worsening of the absorption in comparison with thienopyridine drugs.
3.P2Y12 inhibitors in acute coronary syndromes: which and when?
Pais P Natl Med J India. 2013 Mar-Apr;26(2):84-90.
Acute coronary syndromes (ACS) are the commonest acute manifestation of coronary artery disease and a major cause of hospitalization and death. Plaque rupture and subsequent platelet activation are the key factors in its pathogenesis. Platelet inhibitors are crucial in the management of ACS. Aspirin remains the standard antiplatelet but use of dual antiplatelet drugs is beneficial in ACS. Platelet P2Y12 receptor inhibitors are an important group of antiplatelet compounds that can be combined with aspirin in the management of ACS. P2Y12 inhibitors may belong to the thienopyridine or nonthienopyridine group of compounds. The former (clopidogrel, prasugrel) combine irreversibly with the receptor and therefore have a prolonged duration of action. On the other hand, the non-thienopyridine compounds (ticagrelor, elinogrel) have a reversible action and hence a shorter duration of action. Several new compounds in this group have become or are likely to become available. The newer agents have a more uniform and complete antiplatelet effect and are much less likely to be affected by genetic variability of CYP2C19 enzyme activity compared with that of clopidogrel. Large phase 3 trials have shown that ticagrelor and prasugrel reduce major cardiovascular events in ACS compared to clopidogrel when given in addition to aspirin.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related P2Y Receptor Products

(CAS: 787548-03-2)

Regrelor is a P2Y12 antagonist. In Dec 2008, Phase-II for Thrombosis in USA was discontinued.

CAS 1279829-64-9 SAR 216471 hydrochloride

SAR 216471 hydrochloride
(CAS: 1279829-64-9)

SAR 216471 hydrochloride is a potent and reversible P2Y12 antagonist (IC50 = 17 nM), displaying antiplatelet and antithrombotic activity in vivo.

Prasugrel Maleic acid
(CAS: 389574-20-3)

Prasugrel is a platelet inhibitor (IC50=1.8 μM) , as a third-generation thienopyridine.

CAS 56583-49-4 PIT

(CAS: 56583-49-4)

PIT selectively and non-competitively blocked P2Y1 receptor signaling without affecting nucleotide binding. PIT had no significant effect on agonist activation ...

CAS 1047980-83-5 MRS 2768 tetrasodium salt

MRS 2768 tetrasodium salt
(CAS: 1047980-83-5)

MRS 2768 tetrasodium salt is a selective P2Y2 agonist (EC50 = 1.89 μM), with no affinity for human P2Y4 or P2Y6 receptors.

CAS 1266569-94-1 UTPγS trisodium salt

UTPγS trisodium salt
(CAS: 1266569-94-1)

UTPγS trisodium salt is a selective P2Y2 and P2Y4 receptor agonist.

CAS 15039-58-4 MRS 2690

MRS 2690
(CAS: 15039-58-4)

MRS 2690 is a potent P2Y14 receptor agonist (EC50 = 49 nM), with 7-fold higher potency than UDP-glucose.

CAS 211427-08-6 Diquafosol tetrasodium

Diquafosol tetrasodium
(CAS: 211427-08-6)

Diquafosol tetrasodium, also referred to Diquas, is aP2Y2receptor agonist that is targeted to treat dry eye disease through rehydration of the ocular surface.

Chemical Structure

CAS 936500-94-6 Elinogrel

Quick Inquiry

Verification code

Featured Items